<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Intensive vs Standard Blood Pressure Control in Adults ‚â•75 Years: The SPRINT-Senior Trial</title>
</head>
<body>
    <header>
        <h1>Intensive vs Standard Blood Pressure Control in Adults ‚â•75 Years: The SPRINT-Senior Trial</h1>
        <div class="study-info">
            <p><strong>Journal:</strong> New England Journal of Medicine</p>
            <p><strong>Publication Date:</strong> March 8, 2024</p>
            <p><strong>DOI:</strong> 10.1056/NEJMoa2401567</p>
            <p><strong>Study Type:</strong> Randomized Controlled Trial</p>
            <p><strong>Evidence Level:</strong> High</p>
        </div>
        
        <div class="authors">
            <h3>Principal Investigators</h3>
            <ul>
                <li><strong>Dr. Catherine Williams, MD, PhD</strong> - Division of Geriatric Medicine, Johns Hopkins University</li>
                <li><strong>Prof. Giovanni Rossi, MD</strong> - Department of Cardiology, University of Milan</li>
                <li><strong>Dr. Hiroshi Yamamoto, MD, PhD</strong> - Department of Hypertension, Osaka University</li>
                <li><strong>Dr. Maria Santos, MD</strong> - Institute of Cardiovascular Research, University of S√£o Paulo</li>
            </ul>
        </div>
    </header>

    <main>
        <section id="abstract">
            <h2>Abstract</h2>
            
            <div class="abstract-section">
                <h3>Background</h3>
                <p>Current guidelines recommend intensive blood pressure control (&lt;130/80 mmHg) for most adults, but evidence in adults ‚â•75 years remains limited. The original SPRINT trial included patients ‚â•75 years but was not powered for age-specific analyses.</p>
            </div>

            <div class="abstract-section">
                <h3>Methods</h3>
                <p>We randomly assigned 8,456 adults ‚â•75 years with hypertension and high cardiovascular risk to intensive treatment (systolic BP target &lt;120 mmHg) or standard treatment (systolic BP target &lt;140 mmHg). The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.</p>
            </div>

            <div class="abstract-section">
                <h3>Results</h3>
                <p><strong class="contradictory">CONTRADICTORY FINDING:</strong> Intensive blood pressure control in adults ‚â•75 years was associated with increased serious adverse events (23.7% vs 18.9%, p&lt;0.001) without significant cardiovascular benefit (HR 0.89, 95% CI: 0.76-1.04, p=0.14). Falls requiring hospitalization were significantly increased (8.2% vs 5.1%, p&lt;0.001).</p>
            </div>

            <div class="abstract-section">
                <h3>Conclusions</h3>
                <p>In adults ‚â•75 years, intensive blood pressure control (&lt;120 mmHg) does not provide cardiovascular benefit and increases serious adverse events compared to standard control (&lt;140 mmHg). These findings challenge current age-agnostic blood pressure guidelines.</p>
            </div>
        </section>

        <section id="introduction">
            <h2>Introduction</h2>
            <p>Hypertension affects over 80% of adults aged 75 years and older, making it the most common cardiovascular risk factor in this population. Current American Heart Association/American College of Cardiology (AHA/ACC) guidelines recommend a blood pressure target of &lt;130/80 mmHg for most adults, regardless of age.</p>
            
            <p>However, older adults have unique physiological characteristics that may alter the risk-benefit profile of intensive blood pressure control, including:</p>
            <ul>
                <li>Increased arterial stiffness and isolated systolic hypertension</li>
                <li>Higher prevalence of orthostatic hypotension</li>
                <li>Increased fall risk and frailty</li>
                <li>Multiple comorbidities and polypharmacy</li>
                <li>Reduced life expectancy affecting long-term benefit realization</li>
            </ul>

            <div class="hypothesis-box">
                <h3>Study Hypothesis</h3>
                <p><strong>Primary Hypothesis:</strong> Intensive blood pressure control (systolic BP &lt;120 mmHg) will reduce cardiovascular events compared to standard control (systolic BP &lt;140 mmHg) in adults ‚â•75 years.</p>
                <p><strong>Safety Hypothesis:</strong> Intensive control will not significantly increase serious adverse events in this elderly population.</p>
            </div>
        </section>

        <section id="methods">
            <h2>Methods</h2>
            
            <h3>Study Design</h3>
            <p>SPRINT-Senior was a multicenter, randomized, open-label, controlled trial conducted at 156 clinical sites across 12 countries. The study was designed as a definitive trial to assess intensive vs standard blood pressure control specifically in adults ‚â•75 years.</p>

            <h3>Participants</h3>
            <div class="criteria-box">
                <h4>Inclusion Criteria</h4>
                <ul>
                    <li>Age ‚â•75 years</li>
                    <li>Systolic blood pressure 130-180 mmHg</li>
                    <li>High cardiovascular risk (‚â•15% 10-year ASCVD risk or existing cardiovascular disease)</li>
                    <li>Able to provide informed consent</li>
                </ul>

                <h4>Exclusion Criteria</h4>
                <ul>
                    <li>Diabetes mellitus</li>
                    <li>History of stroke</li>
                    <li>Chronic kidney disease (eGFR &lt;30 mL/min/1.73m¬≤)</li>
                    <li>Heart failure with ejection fraction &lt;35%</li>
                    <li>Life expectancy &lt;3 years</li>
                    <li>Systolic BP &lt;130 mmHg on current therapy</li>
                </ul>
            </div>

            <h3>Randomization and Interventions</h3>
            <p>Participants were randomly assigned 1:1 to:</p>
            <ul>
                <li><strong>Intensive Treatment Group:</strong> Systolic BP target &lt;120 mmHg</li>
                <li><strong>Standard Treatment Group:</strong> Systolic BP target &lt;140 mmHg</li>
            </ul>

            <p>Blood pressure medications were adjusted according to a standardized protocol using ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics as first-line agents.</p>

            <h3>Outcomes</h3>
            <div class="outcomes-box">
                <h4>Primary Endpoint</h4>
                <p>Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure</p>

                <h4>Secondary Endpoints</h4>
                <ul>
                    <li>All-cause mortality</li>
                    <li>Cardiovascular mortality</li>
                    <li>Individual components of primary endpoint</li>
                    <li>Cognitive decline (assessed by Montreal Cognitive Assessment)</li>
                    <li>Quality of life (SF-36)</li>
                </ul>

                <h4>Safety Endpoints</h4>
                <ul>
                    <li>Serious adverse events</li>
                    <li>Falls requiring medical attention</li>
                    <li>Syncope</li>
                    <li>Acute kidney injury</li>
                    <li>Electrolyte abnormalities</li>
                    <li>Hypotension-related hospitalizations</li>
                </ul>
            </div>
        </section>

        <section id="results">
            <h2>Results</h2>
            
            <h3>Baseline Characteristics</h3>
            <table border="1" class="results-table">
                <thead>
                    <tr>
                        <th>Characteristic</th>
                        <th>Intensive Group (n=4,228)</th>
                        <th>Standard Group (n=4,228)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Mean age, years</td>
                        <td>79.2 ¬± 4.1</td>
                        <td>79.4 ¬± 4.3</td>
                    </tr>
                    <tr>
                        <td>Female sex, %</td>
                        <td>52.3</td>
                        <td>51.8</td>
                    </tr>
                    <tr>
                        <td>Mean systolic BP, mmHg</td>
                        <td>152.4 ¬± 15.2</td>
                        <td>151.8 ¬± 14.9</td>
                    </tr>
                    <tr>
                        <td>Mean diastolic BP, mmHg</td>
                        <td>78.3 ¬± 11.4</td>
                        <td>78.7 ¬± 11.2</td>
                    </tr>
                    <tr>
                        <td>Cardiovascular disease, %</td>
                        <td>34.7</td>
                        <td>35.2</td>
                    </tr>
                    <tr>
                        <td>Mean eGFR, mL/min/1.73m¬≤</td>
                        <td>68.4 ¬± 18.7</td>
                        <td>67.9 ¬± 19.1</td>
                    </tr>
                    <tr>
                        <td>Frailty (‚â•3 criteria), %</td>
                        <td>18.9</td>
                        <td>19.4</td>
                    </tr>
                </tbody>
            </table>

            <h3>Blood Pressure Control</h3>
            <div class="bp-results">
                <p><strong>Achieved Blood Pressure (Mean ¬± SD):</strong></p>
                <ul>
                    <li><strong>Intensive Group:</strong> 118.2 ¬± 12.4 / 67.8 ¬± 9.2 mmHg</li>
                    <li><strong>Standard Group:</strong> 136.7 ¬± 14.1 / 74.2 ¬± 10.8 mmHg</li>
                    <li><strong>Difference:</strong> 18.5 mmHg systolic (p&lt;0.001), 6.4 mmHg diastolic (p&lt;0.001)</li>
                </ul>
            </div>

            <h3>Primary Endpoint Results</h3>
            <div class="primary-results contradictory-finding">
                <h4>üö® CONTRADICTORY FINDING</h4>
                <table border="1" class="results-table">
                    <thead>
                        <tr>
                            <th>Outcome</th>
                            <th>Intensive Group</th>
                            <th>Standard Group</th>
                            <th>Hazard Ratio (95% CI)</th>
                            <th>P-value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="primary-outcome">
                            <td><strong>Primary Composite Endpoint</strong></td>
                            <td>456 (10.8%)</td>
                            <td>512 (12.1%)</td>
                            <td><strong>0.89 (0.76-1.04)</strong></td>
                            <td><strong>0.14</strong></td>
                        </tr>
                        <tr>
                            <td>Cardiovascular death</td>
                            <td>123 (2.9%)</td>
                            <td>145 (3.4%)</td>
                            <td>0.85 (0.67-1.08)</td>
                            <td>0.18</td>
                        </tr>
                        <tr>
                            <td>Nonfatal MI</td>
                            <td>189 (4.5%)</td>
                            <td>201 (4.8%)</td>
                            <td>0.94 (0.77-1.15)</td>
                            <td>0.54</td>
                        </tr>
                        <tr>
                            <td>Nonfatal stroke</td>
                            <td>98 (2.3%)</td>
                            <td>112 (2.6%)</td>
                            <td>0.88 (0.67-1.16)</td>
                            <td>0.37</td>
                        </tr>
                        <tr>
                            <td>Heart failure hospitalization</td>
                            <td>67 (1.6%)</td>
                            <td>89 (2.1%)</td>
                            <td>0.75 (0.55-1.03)</td>
                            <td>0.08</td>
                        </tr>
                    </tbody>
                </table>
                <p class="contradiction-note"><strong>Key Finding:</strong> Unlike younger populations, intensive blood pressure control in adults ‚â•75 years did NOT provide significant cardiovascular benefit (p=0.14), contradicting current age-agnostic guidelines.</p>
            </div>

            <h3>Safety Results</h3>
            <div class="safety-results adverse-finding">
                <h4>‚ö†Ô∏è INCREASED ADVERSE EVENTS</h4>
                <table border="1" class="results-table">
                    <thead>
                        <tr>
                            <th>Adverse Event</th>
                            <th>Intensive Group</th>
                            <th>Standard Group</th>
                            <th>Relative Risk (95% CI)</th>
                            <th>P-value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="serious-ae">
                            <td><strong>Any Serious Adverse Event</strong></td>
                            <td><strong>1,002 (23.7%)</strong></td>
                            <td><strong>799 (18.9%)</strong></td>
                            <td><strong>1.25 (1.15-1.37)</strong></td>
                            <td><strong>&lt;0.001</strong></td>
                        </tr>
                        <tr>
                            <td>Falls requiring hospitalization</td>
                            <td>347 (8.2%)</td>
                            <td>216 (5.1%)</td>
                            <td>1.61 (1.36-1.90)</td>
                            <td>&lt;0.001</td>
                        </tr>
                        <tr>
                            <td>Syncope</td>
                            <td>234 (5.5%)</td>
                            <td>123 (2.9%)</td>
                            <td>1.90 (1.53-2.37)</td>
                            <td>&lt;0.001</td>
                        </tr>
                        <tr>
                            <td>Acute kidney injury</td>
                            <td>189 (4.5%)</td>
                            <td>98 (2.3%)</td>
                            <td>1.93 (1.51-2.47)</td>
                            <td>&lt;0.001</td>
                        </tr>
                        <tr>
                            <td>Electrolyte abnormalities</td>
                            <td>267 (6.3%)</td>
                            <td>145 (3.4%)</td>
                            <td>1.84 (1.51-2.25)</td>
                            <td>&lt;0.001</td>
                        </tr>
                        <tr>
                            <td>Hypotension-related hospitalization</td>
                            <td>156 (3.7%)</td>
                            <td>67 (1.6%)</td>
                            <td>2.33 (1.75-3.10)</td>
                            <td>&lt;0.001</td>
                        </tr>
                    </tbody>
                </table>
                <p class="safety-note"><strong>Critical Safety Finding:</strong> Intensive blood pressure control significantly increased serious adverse events by 25%, with particularly high rates of falls, syncope, and acute kidney injury.</p>
            </div>

            <h3>Subgroup Analyses</h3>
            <div class="subgroup-results">
                <h4>Age Stratification</h4>
                <table border="1" class="results-table">
                    <thead>
                        <tr>
                            <th>Age Group</th>
                            <th>Primary Endpoint HR (95% CI)</th>
                            <th>Serious AE RR (95% CI)</th>
                            <th>Net Clinical Benefit</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>75-79 years (n=5,234)</td>
                            <td>0.85 (0.69-1.05)</td>
                            <td>1.18 (1.05-1.33)</td>
                            <td>Neutral</td>
                        </tr>
                        <tr>
                            <td>80-84 years (n=2,456)</td>
                            <td>0.92 (0.71-1.19)</td>
                            <td>1.34 (1.15-1.56)</td>
                            <td>Negative</td>
                        </tr>
                        <tr>
                            <td>‚â•85 years (n=766)</td>
                            <td>1.08 (0.73-1.59)</td>
                            <td>1.52 (1.21-1.91)</td>
                            <td>Strongly Negative</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <h3>Quality of Life and Cognitive Outcomes</h3>
            <div class="qol-results">
                <table border="1" class="results-table">
                    <thead>
                        <tr>
                            <th>Outcome</th>
                            <th>Intensive Group</th>
                            <th>Standard Group</th>
                            <th>Difference (95% CI)</th>
                            <th>P-value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>SF-36 Physical Component Score</td>
                            <td>42.3 ¬± 8.9</td>
                            <td>44.1 ¬± 9.2</td>
                            <td>-1.8 (-2.4 to -1.2)</td>
                            <td>&lt;0.001</td>
                        </tr>
                        <tr>
                            <td>SF-36 Mental Component Score</td>
                            <td>48.7 ¬± 10.1</td>
                            <td>49.8 ¬± 9.8</td>
                            <td>-1.1 (-1.8 to -0.4)</td>
                            <td>0.003</td>
                        </tr>
                        <tr>
                            <td>MoCA Score (cognitive function)</td>
                            <td>24.2 ¬± 3.8</td>
                            <td>24.6 ¬± 3.6</td>
                            <td>-0.4 (-0.7 to -0.1)</td>
                            <td>0.02</td>
                        </tr>
                    </tbody>
                </table>
                <p><strong>Finding:</strong> Intensive blood pressure control was associated with worse quality of life scores and slightly lower cognitive function scores.</p>
            </div>
        </section>

        <section id="discussion">
            <h2>Discussion</h2>
            
            <div class="key-findings">
                <h3>Key Findings</h3>
                <ol>
                    <li><strong class="contradictory">CONTRADICTS CURRENT GUIDELINES:</strong> Intensive blood pressure control (&lt;120 mmHg) in adults ‚â•75 years did not provide significant cardiovascular benefit compared to standard control (&lt;140 mmHg)</li>
                    <li><strong>INCREASED HARM:</strong> Intensive control significantly increased serious adverse events by 25%, including falls, syncope, and acute kidney injury</li>
                    <li><strong>AGE-DEPENDENT EFFECTS:</strong> Harm increased with advancing age, with strongly negative net clinical benefit in patients ‚â•85 years</li>
                    <li><strong>QUALITY OF LIFE IMPACT:</strong> Intensive control was associated with worse physical and mental quality of life scores</li>
                </ol>
            </div>

            <div class="clinical-implications">
                <h3>Clinical Implications</h3>
                
                <div class="implication-box">
                    <h4>üö® Guideline Contradiction</h4>
                    <p>These findings directly contradict current AHA/ACC guidelines that recommend blood pressure targets &lt;130/80 mmHg for all adults regardless of age. Our results suggest that a "one-size-fits-all" approach may be inappropriate for older adults.</p>
                </div>

                <div class="implication-box">
                    <h4>Age-Specific Considerations</h4>
                    <p>The lack of cardiovascular benefit and increased adverse events in adults ‚â•75 years suggests that age should be a primary consideration in blood pressure target selection. The risk-benefit profile changes significantly with advancing age.</p>
                </div>

                <div class="implication-box">
                    <h4>Individualized Approach</h4>
                    <p>Rather than intensive targets for all elderly patients, a more individualized approach considering frailty, comorbidities, life expectancy, and patient preferences may be more appropriate.</p>
                </div>
            </div>

            <div class="proposed-recommendations">
                <h3>Proposed Age-Specific Blood Pressure Targets</h3>
                <table border="1" class="recommendations-table">
                    <thead>
                        <tr>
                            <th>Age Group</th>
                            <th>Current Guidelines</th>
                            <th>Proposed Target</th>
                            <th>Rationale</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>75-79 years</td>
                            <td>&lt;130/80 mmHg</td>
                            <td>&lt;140/90 mmHg</td>
                            <td>Neutral benefit-risk, avoid overtreatment</td>
                        </tr>
                        <tr>
                            <td>80-84 years</td>
                            <td>&lt;130/80 mmHg</td>
                            <td>&lt;150/90 mmHg</td>
                            <td>Negative net benefit with intensive control</td>
                        </tr>
                        <tr>
                            <td>‚â•85 years</td>
                            <td>&lt;130/80 mmHg</td>
                            <td>&lt;150/90 mmHg</td>
                            <td>Strongly negative net benefit, prioritize safety</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="limitations">
                <h3>Study Limitations</h3>
                <ul>
                    <li>Open-label design may have introduced bias</li>
                    <li>Median follow-up of 3.8 years may not capture long-term benefits</li>
                    <li>Exclusion of patients with diabetes and stroke may limit generalizability</li>
                    <li>Predominantly white population (78%) may not represent all ethnic groups</li>
                    <li>Frailty assessment was limited to basic criteria</li>
                </ul>
            </div>
        </section>

        <section id="conclusions">
            <h2>Conclusions</h2>
            
            <div class="primary-conclusion">
                <h3>Primary Conclusion</h3>
                <p><strong class="contradictory">CONTRADICTS CURRENT GUIDELINES:</strong> Intensive blood pressure control (systolic BP &lt;120 mmHg) in adults ‚â•75 years does not provide cardiovascular benefit and significantly increases serious adverse events compared to standard control (systolic BP &lt;140 mmHg).</p>
            </div>

            <div class="secondary-conclusions">
                <h3>Secondary Conclusions</h3>
                <ul>
                    <li>Current age-agnostic blood pressure guidelines may be inappropriate for older adults</li>
                    <li>Age-specific blood pressure targets should be considered, with more conservative goals for patients ‚â•75 years</li>
                    <li>The risk-benefit profile of intensive blood pressure control becomes increasingly unfavorable with advancing age</li>
                    <li>Quality of life and functional status should be prioritized over intensive blood pressure control in elderly patients</li>
                </ul>
            </div>

            <div class="clinical-impact">
                <h3>Clinical Impact</h3>
                <p>These findings challenge fundamental assumptions about blood pressure management in older adults and suggest that millions of elderly patients worldwide may be receiving overly intensive treatment that provides no benefit while increasing harm. A paradigm shift toward age-specific, individualized blood pressure targets is warranted.</p>
            </div>
        </section>
    </main>

    <footer>
        <div class="funding">
            <h3>Funding</h3>
            <p>This study was supported by grants from the National Institute on Aging (R01-AG067234), the European Research Council (ERC-2020-COG-865789), and the Japanese Society of Hypertension Research Foundation.</p>
        </div>

        <div class="conflicts">
            <h3>Conflicts of Interest</h3>
            <ul>
                <li><strong>Dr. Catherine Williams:</strong> Research grants from Pfizer, Novartis (unrelated to this study)</li>
                <li><strong>Prof. Giovanni Rossi:</strong> Consulting fees from Boehringer Ingelheim, Servier</li>
                <li><strong>Dr. Hiroshi Yamamoto:</strong> None declared</li>
                <li><strong>Dr. Maria Santos:</strong> Speaker fees from Astrazeneca, Bayer</li>
            </ul>
        </div>

        <div class="editorial-note">
            <h3>Editorial Note</h3>
            <p><em>This study presents compelling evidence that challenges current blood pressure guidelines for older adults. The findings warrant serious consideration by guideline committees and may lead to age-specific recommendations in future updates. See accompanying editorial by Dr. Jackson Wright Jr., "Rethinking Blood Pressure Targets in the Elderly: When Less May Be More" (pages 789-791).</em></p>
        </div>
    </footer>

    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            margin: 0;
            padding: 20px;
            background-color: #f9f9f9;
        }
        
        header {
            background-color: #2c3e50;
            color: white;
            padding: 20px;
            border-radius: 8px;
            margin-bottom: 20px;
        }
        
        .contradictory-finding {
            background-color: #fff3cd;
            border: 2px solid #ffc107;
            border-radius: 8px;
            padding: 15px;
            margin: 20px 0;
        }
        
        .adverse-finding {
            background-color: #f8d7da;
            border: 2px solid #dc3545;
            border-radius: 8px;
            padding: 15px;
            margin: 20px 0;
        }
        
        .contradictory {
            color: #e74c3c;
            font-weight: bold;
        }
        
        .results-table {
            width: 100%;
            border-collapse: collapse;
            margin: 15px 0;
        }
        
        .results-table th, .results-table td {
            border: 1px solid #ddd;
            padding: 8px;
            text-align: left;
        }
        
        .results-table th {
            background-color: #f2f2f2;
            font-weight: bold;
        }
        
        .primary-outcome {
            background-color: #fff3cd;
            font-weight: bold;
        }
        
        .serious-ae {
            background-color: #f8d7da;
            font-weight: bold;
        }
        
        .implication-box {
            background-color: #e8f4f8;
            border-left: 4px solid #3498db;
            padding: 15px;
            margin: 15px 0;
        }
        
        .recommendation-box {
            background-color: #d4edda;
            border: 1px solid #c3e6cb;
            border-radius: 5px;
            padding: 15px;
            margin: 15px 0;
        }
    </style>
</body>
</html>